CONDENSED CONSOLIDATED STATEMENTS OF CONTINGENTLY REDEEMABLE COMMON STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock	Additional Paid-In Capital	Accumulated Deficit	AOCI Attributable to Parent [Member]	Noncontrolling Interests	Contingently Redeemable Common Stock	IPO	IPO Common Stock	IPO Additional Paid-In Capital	IPO Contingently Redeemable Common Stock
Beginning balance at Dec. 31, 2020	$ (284,730)	$ 2,494	$ 263,966	$ (551,190)		$ 0
Contingently Redeemable Common Stock, Beginning balance, shares at Dec. 31, 2020							76,201
Contingently Redeemable Common Stock, Beginning balance at Dec. 31, 2020							$ 309,500
Beginning balance, shares at Dec. 31, 2020		249,374
Net income (loss)	(314,092)			(313,923)		(169)
Reclassification of contingently redeemable common stock in connection with initial public offering ("IPO"), Shares									76,201		76,201
Reclassification of contingently redeemable common stock in connection with initial public offering ("IPO")								$ 309,500	$ 762	$ 308,738	$ (309,500)
Issuance of common stock in connection with IPO, net of offering costs, Shares									53,590
Issuance of common stock in connection with IPO, net of offering costs								1,163,029	$ 536	1,162,493
Issuance of common stock under partner physician group equity agreements upon IPO, Shares									11,672
Issuance of common stock under partner physician group equity agreements upon IPO								268,467	$ 117	268,350
Exercise of stock options and other, net	551		551
Exercise of stock options and other, net, shares		46
Stock-based compensation expense	7,553		7,553
Ending balance at Jun. 30, 2021	1,150,278	$ 3,909	2,011,651	(865,113)		(169)
Contingently Redeemable Common Stock, Ending balance, shares at Jun. 30, 2021							0
Contingently Redeemable Common Stock, Ending balance at Jun. 30, 2021							$ 0
Ending balance, shares at Jun. 30, 2021		390,883
Beginning balance at Mar. 31, 2021	(298,244)	$ 2,494	265,603	(566,268)		(73)
Contingently Redeemable Common Stock, Beginning balance, shares at Mar. 31, 2021							76,201
Contingently Redeemable Common Stock, Beginning balance at Mar. 31, 2021							$ 309,500
Beginning balance, shares at Mar. 31, 2021		249,474
Net income (loss)	(298,941)			(298,845)		(96)
Reclassification of contingently redeemable common stock in connection with initial public offering ("IPO"), Shares									76,201		(76,201)
Reclassification of contingently redeemable common stock in connection with initial public offering ("IPO")								309,500	$ 762	308,738	$ (309,500)
Issuance of common stock in connection with IPO, net of offering costs, Shares									53,590
Issuance of common stock in connection with IPO, net of offering costs								1,163,029	$ 536	1,162,493
Issuance of common stock under partner physician group equity agreements upon IPO, Shares									11,672
Issuance of common stock under partner physician group equity agreements upon IPO								$ 268,467	$ 117	$ 268,350
Exercise of stock options and other, net	386		386
Exercise of stock options and other, net, shares		54
Stock-based compensation expense	6,081		6,081
Ending balance at Jun. 30, 2021	1,150,278	$ 3,909	2,011,651	(865,113)		(169)
Contingently Redeemable Common Stock, Ending balance, shares at Jun. 30, 2021							0
Contingently Redeemable Common Stock, Ending balance at Jun. 30, 2021							$ 0
Ending balance, shares at Jun. 30, 2021		390,883
Beginning balance at Dec. 31, 2021	$ 1,091,596	$ 4,001	2,045,572	(957,677)		(300)
Beginning balance, shares at Dec. 31, 2021	400,095	400,095
Net income (loss)	$ (19,576)			(19,419)		(157)
Exercise of stock options and other, net	21,073	$ 80	20,993
Exercise of stock options and other, net, shares		8,002
Other comprehensive income (loss)	$ 513				513
Costs of RSU Vestings, Shares		140
Costs of RSU Vestings		$ 1	$ (1)
Shares withheld related to net share settlement, Shares		33
Shares withheld related to net share settlement	(758)		(758)
Stock-based compensation expense	$ 10,523		$ 10,523
Ending balance at Jun. 30, 2022	$ 1,103,371	$ 4,082	2,076,329	(977,096)	513	(457)
Ending balance, shares at Jun. 30, 2022	408,204	408,204
Beginning balance at Mar. 31, 2022	$ 1,111,477	$ 4,057	2,064,242	(956,447)		(375)
Beginning balance, shares at Mar. 31, 2022		405,727
Net income (loss)	(20,731)			(20,649)		(82)
Exercise of stock options and other, net	6,317	$ 24	6,293
Exercise of stock options and other, net, shares		2,370
Other comprehensive income (loss)	$ 513				513
Costs of RSU Vestings, Shares		140
Costs of RSU Vestings		$ 1	$ (1)
Shares withheld related to net share settlement, Shares		33
Shares withheld related to net share settlement	(758)		(758)
Stock-based compensation expense	$ 6,553		$ 6,553
Ending balance at Jun. 30, 2022	$ 1,103,371	$ 4,082	$ 2,076,329	$ (977,096)	$ 513	$ (457)
Ending balance, shares at Jun. 30, 2022	408,204	408,204